EA201190109A1 - Изолированные популяции моноцитов и связанные с ними терапевтические применения - Google Patents

Изолированные популяции моноцитов и связанные с ними терапевтические применения

Info

Publication number
EA201190109A1
EA201190109A1 EA201190109A EA201190109A EA201190109A1 EA 201190109 A1 EA201190109 A1 EA 201190109A1 EA 201190109 A EA201190109 A EA 201190109A EA 201190109 A EA201190109 A EA 201190109A EA 201190109 A1 EA201190109 A1 EA 201190109A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monocytes
sample
isolated
red blood
blood cells
Prior art date
Application number
EA201190109A
Other languages
English (en)
Inventor
Мартин Фридлэндер
Мэтью Р. Риттер
Стейси К. Морено
Мохаммед А. Эль-Калай
Original Assignee
Зе Скрипс Ресеч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зе Скрипс Ресеч Инститьют filed Critical Зе Скрипс Ресеч Инститьют
Publication of EA201190109A1 publication Critical patent/EA201190109A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4614—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/051—Lipid A (MPA, MPL)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/04—Investigating sedimentation of particle suspensions
    • G01N15/042—Investigating sedimentation of particle suspensions by centrifuging and investigating centrifugates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N15/149—Optical investigation techniques, e.g. flow cytometry specially adapted for sorting particles, e.g. by their size or optical properties
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Optical investigation techniques, e.g. flow cytometry
    • G01N2015/1497—Particle shape

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Согласно настоящему изобретению предложены способы применения изолированных популяций моноцитов для лечения субъектов, страдающих от различных сосудистых заболеваний глаз или дегенеративных расстройств глаз. Согласно настоящему изобретению также предложены новые способы выделения, по существу, чистых популяций моноцитов. Указанные способы включают получение образца крови или образца костного мозга от субъекта, уменьшение количества красных кровяных клеток в указанном образце, а затем отделение оставшихся в образце красных кровяных клеток и других типов клеток от моноцитов. Вместо применения каких-либо селективных или вводящих метку агентов красные кровяные клетки и другие типы клеток отделяют от моноцитов на основании их размера, гранулярности или плотности. Изолированные моноциты можно дополнительно активировать in vitro или ex vivo перед введением субъекту. Согласно настоящему изобретению также предложены изолированные популяции клеток, содержащие, по существу, чистые моноциты CD14/CD33.
EA201190109A 2009-02-20 2010-02-19 Изолированные популяции моноцитов и связанные с ними терапевтические применения EA201190109A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20817309P 2009-02-20 2009-02-20
US28324409P 2009-11-30 2009-11-30
PCT/US2010/000477 WO2010096177A1 (en) 2009-02-20 2010-02-19 Isolated monocyte populations and related therapeutic applications

Publications (1)

Publication Number Publication Date
EA201190109A1 true EA201190109A1 (ru) 2012-07-30

Family

ID=42634163

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190109A EA201190109A1 (ru) 2009-02-20 2010-02-19 Изолированные популяции моноцитов и связанные с ними терапевтические применения

Country Status (11)

Country Link
EP (1) EP2398900A4 (ru)
JP (1) JP2012518407A (ru)
KR (1) KR20110123778A (ru)
CN (1) CN102317446A (ru)
AU (1) AU2010216374A1 (ru)
BR (1) BRPI1008392A2 (ru)
CA (1) CA2752679A1 (ru)
EA (1) EA201190109A1 (ru)
MX (1) MX2011008826A (ru)
WO (1) WO2010096177A1 (ru)
ZA (1) ZA201105869B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377273A (zh) * 2013-05-22 2016-03-02 耶达研究与发展公司 用于治疗眼睛疾病或病症的人类单核细胞亚群
KR101668462B1 (ko) * 2015-02-26 2016-10-24 충북대학교 산학협력단 혈액성분을 유효성분으로 포함하는 녹내장의 예방 또는 치료용 약제학적 조성물
FR3084463B1 (fr) * 2018-07-30 2023-04-21 Francais Du Sang Ets Procede d'analyse des plaquettes d'un echantillon sanguin
CN114441419B (zh) * 2022-01-29 2022-11-22 杭州翔宇医学检验实验室有限公司 流式圈门方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006031467A2 (en) * 2002-07-25 2006-03-23 The Scripps Research Institute Isolated lineage negative hematopoietic stem cells and methods of treatment therewith
EP1718735A1 (en) * 2004-02-11 2006-11-08 Aldagen, Inc. Stem cell populations and methods of use
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
CA2656463C (en) * 2006-06-28 2015-12-01 Yeda Research And Development Co. Ltd. Method of treatment of age-related macular degeneration

Also Published As

Publication number Publication date
BRPI1008392A2 (pt) 2015-08-25
CN102317446A (zh) 2012-01-11
KR20110123778A (ko) 2011-11-15
CA2752679A1 (en) 2010-08-26
WO2010096177A1 (en) 2010-08-26
EP2398900A1 (en) 2011-12-28
AU2010216374A1 (en) 2011-08-18
EP2398900A4 (en) 2012-08-22
ZA201105869B (en) 2012-10-31
JP2012518407A (ja) 2012-08-16
MX2011008826A (es) 2011-11-02

Similar Documents

Publication Publication Date Title
Yin et al. Roles of extracellular vesicles in the aging microenvironment and age‐related diseases
Cicero et al. Extracellular vesicles shuffling intercellular messages: for good or for bad
Zhao et al. Dose-effect relationship and molecular mechanism by which BMSC-derived exosomes promote peripheral nerve regeneration after crush injury
Grisendi et al. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion
Ryu et al. Tonsil-derived mesenchymal stem cells alleviate concanavalin A-induced acute liver injury
Henao Agudelo et al. Mesenchymal stromal cell-derived microvesicles regulate an internal pro-inflammatory program in activated macrophages
Dong et al. Differential fates of tissue macrophages in the cochlea during postnatal development
Vieira Paladino et al. The immunomodulatory potential of Wharton’s jelly mesenchymal stem/stromal cells
Ratajczak et al. Stem cells for neural regeneration-a potential application of very small embryonic-like stem cells
ES2784183T3 (es) Procedimientos de uso y aparato para modulación inmunitaria de células madre
EA201990583A1 (ru) Клеточная суспензия для использования в лечении заболевания периферических артерий нижних конечностей
Mohammadi et al. Isolation and characterization of microvesicles from mesenchymal stem cells
KR20160035087A (ko) 줄기 세포 마이크로입자 및 miRNA
BR112012024350A2 (pt) métodos para tratar paciente atraves da separação de ctcs, para capturar células de tumor circulantes (ctc) em fluido corporal e para descobrir fármacos, ctcs isoladas, filtro de captura de ctcs em fluido corporal e dispositivos extracorpóreos para a captura de ctcs em fluido corporal
ES2873877T3 (es) Composiciones y métodos para disminuir una respuesta inmune
CN112795533A (zh) 从细胞培养上清液和生物流体分离并纯化微泡的方法
WO2008101104A3 (en) Aligned nanofibers and related methods of use
EA201190109A1 (ru) Изолированные популяции моноцитов и связанные с ними терапевтические применения
WO2013126590A3 (en) Pharmaceutical composition comprising cd34+ cells
MX2010005863A (es) Proceso para reducir los efectos de la enfermedad injerto contra receptor con el uso de celulas t reguladoras cd4+cd25+ expandidas ex vivo.
Yang et al. Endometrial mesenchymal stem/stromal cell modulation of T cell proliferation
Fajka-Boja et al. Galectin-1 is a local but not systemic immunomodulatory factor in mesenchymal stromal cells
DE602006013453D1 (de) Verfahren zur anreicherung fötaler zellen
DE602005017812D1 (de) Multipotente blutstammzellen aus der nabelschnur und zellbehandlungsmittel damit zur behandlung der ischämischen krankheit
Casadei et al. IMT504 blocks allodynia in rats with spared nerve injury by promoting the migration of mesenchymal stem cells and by favoring an anti-inflammatory milieu at the injured nerve